GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley filed a Form 4 on September 18, 2026, reporting the vesting of restricted stock units and a related "sell to cover" transaction in Class A Common Stock on September 16, 2026.
Key Highlights
- RSU Settlement: 7,197 restricted stock units vested and were settled into 7,197 shares of Class A Common Stock at $0 cost on September 16, 2026.
- Tax-Withholding Sales: A total of 3,728 shares were sold across five transactions to satisfy tax withholding obligations in connection with the RSU vesting.
- Sale Price Range: The shares were sold at weighted average prices ranging from $94.258 to $98.995 per share, with individual transaction ranges spanning $94.23 to $99.305 per share.
- Remaining Direct Holdings: Following the transactions, Feeley directly held 44,945 shares of Class A Common Stock.
- Additional Unvested Awards: According to the filing, Feeley also held RSUs representing contingent rights to receive up to 71,667 shares and options to purchase up to 25,906 shares of Class A Common Stock, vesting according to their respective terms.
- Sell-to-Cover Disclosure: The filing states the sales "do not represent a discretionary transaction by the Reporting Person" and were solely to fund tax withholding obligations.
GeneDx CFO's RSU Vesting Details and Share Sales on September 16, 2026
According to the Form 4 filed with the SEC, Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), reported that 7,197 restricted stock units settled into an equal number of Class A Common Stock shares on September 16, 2026. The filing notes that each RSU represents "a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration." The RSUs vest at a rate of 6.25% of the total award quarterly, with the first tranche having vested on June 16, 2023, subject to continued service.
Following the RSU settlement, the filing reports that Feeley sold 3,728 shares in five separate tranches, all on September 16, 2026. The filing states these sales represent shares "sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs" and that the transaction "does not represent a discretionary transaction by the Reporting Person." The weighted average sale prices per tranche were $94.258, $95.405, $96.9009, $98.27, and $98.995, with individual trade prices spanning $94.23 to $99.305 across all tranches.
After all reported transactions, the filing discloses that Feeley directly owned 44,945 shares of Class A Common Stock. In addition, he held RSUs representing contingent rights to receive up to an aggregate 71,667 shares and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, with those awards vesting according to their respective terms. The Form 4 was signed by Bridget Brown as Attorney-in-Fact and filed on September 18, 2026.
What Was Disclosed
The filing reports the settlement of 7,197 RSUs into Class A Common Stock shares and the subsequent sale of 3,728 shares to cover tax withholding obligations by GeneDx Holdings CFO Kevin Feeley, leaving him with 44,945 directly held shares as of September 16, 2026.



Please wait processing your request...